Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
HLNDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| May 14, 2026 | $0.13 | 2026-04-10 | 2026-04-10 |
| September 18, 2025 | $0.06 | 2025-08-15 | 2025-08-15 |
| June 5, 2025 | $0.12 | 2025-04-25 | 2025-04-25 |
| September 19, 2024 | $0.05 | 2024-08-16 | 2024-08-16 |
| May 16, 2024 | $0.11 | 2024-03-14 | 2024-03-15 |
Dividends Summary
- Consistent Payer: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) has rewarded shareholders with 7 dividend payments over the past 3 years.
- Total Returned Value: Investors who held HLN shares during this period received a total of $0.58 per share in dividend income.
- Latest Payout: The most recent dividend of $0.13/share was paid 65 days ago, on May 14, 2026.
- Dividend Growth: Since 2023, the dividend payout has grown by 123.2%, from $0.06 to $0.13.
Company News
The global dietary supplements market is projected to grow from USD 151.82 billion in 2026 to USD 187.22 billion by 2031 at a CAGR of 4.28%. Growth is driven by preventive healthcare adoption, aging populations, and shifting consumer preferences toward convenient formats like gummies and liquids. Asia-Pacific leads market share, while clean-label...
Pfizer has sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the second half.
Haleon, the maker of Sensodyne toothpaste, reported a 0.6% decline in revenue for 2024 but expects 4-6% organic revenue growth in 2025, with stronger performance in the second half of the year. The company faces foreign exchange headwinds that may impact revenue and profit.
Dr Reddy's Laboratories reported a 16% increase in Q3 revenue, driven by its newly acquired Nicotine Replacement Therapy (NRT) portfolio and growth in emerging markets. The company's global generics revenue grew 17% year-over-year, with 7% growth excluding NRT contributions.
Pfizer is expected to provide its 2025 financial guidance on Tuesday. Goldman Sachs projects Pfizer's 2025 EPS to be higher than consensus, driven by strong Paxlovid sales, though Vyndaqel forecast misses consensus.
